

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/588,409
				Filing Date	May 6, 2009
				First Named Inventor	TIDMARSH, George
				Art Unit	1623
Examiner Name	SCHMIDTMANN, Bahar				
Sheet	1	of	2	Attorney Docket Number	92653-715566 (004010US)

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	1	EP	1711188	A2	08-25-2005	Threshold Pharmaceuticals, Inc.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	2	Cancer Drug Information, National Cancer Institute : 7 pages, retrieved on 10/6/2011 from <URL: http://www.cancer.gov/cancertopics/druginfo/alphalist >	<input type="checkbox"/>
	3	CHIOREAN et al., "A Phase 2 Trial of Glufosfamide in Combination With Geemcitabine in Chemotherapy-Naïve Pancreatic Adenocarcinoma," <u>American Journal of Clinical Oncology</u> , 33(2):111-116 (April 2010).	<input type="checkbox"/>
	4	CIULEANU et al., "A Randomized Phase III Trial of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine," <u>European Journal of Cancer</u> 45:1589-1596 (2009).	<input type="checkbox"/>
	5	HERTZBERG et al., "Outpatient-Based Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy in Transplant-Eligible Patients With Non-Hodgkin's Lymphoma and Hodgkin's Disease," <u>Annals of Oncology</u> , 14(Supplement 1):i11-i16 (2003).	<input type="checkbox"/>
	6	OKADA et al., "Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer," <u>Jpn. J. Clin Oncol.</u> , 31(1)7-12 (2001).	<input type="checkbox"/>
	7	SEKER et al., "Mechanistic Aspects of The Cytotoxic Activity of Glufodfamide, a New Tumor Therapeutic Agent," <u>British Journal of Cancer</u> , 82(3):629-634 (2000).	<input type="checkbox"/>
	8	SMITH et al., A Phase II/III Study Comparing Intravenous ZD9331 With Gemcitabine in Patients With Pancreatic Cancer," <u>European Journal of Cancer</u> , 39(10):1377-1383 (07-01-2003).	<input type="checkbox"/>

Examiner Signature	/Bahar Schmidtman/	Date Considered	01/02/2012
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

63779639 v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/588,409
				Filing Date	May 6, 2009
				First Named Inventor	TIDMARSH, George
				Art Unit	1623
Examiner Name	SCHMIDTMANN, Bahar				
Sheet	2	of	2	Attorney Docket Number	92653-715566 (004010US)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	9	Tarceva Erlotinib Tablets – Highlights of Prescription Information, 6 Pages, Revised April 2010.	<input type="checkbox"/>

	10	European Supplementary Report dated August 26, 2009 from European Patent Application No. EP 05712714.	<input type="checkbox"/>
	11	Notice to File a Response (Preliminary Rejection) from Korean Patent Application No. 10-2006-7017702 dated August 16, 2011.	<input type="checkbox"/>
	12	Notice of Reasons for Rejection from Japanese Patent Application No. 2006-552230 dated September 5, 2011. (Japanese Language Only).	<input type="checkbox"/>

Examiner Signature	/Bahar Schmidtman/	Date Considered	01/02/2012
-----------------------	--------------------	--------------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.